DHR Stock Risk Analysis
DHR is a NYSE-listed stock with lower risk characteristics — a DredgeCap risk score of 2.8/10. No dominant structural financial risk is flagged in the most recent SEC filings; the primary considerations for existing shareholders are discussed in the analysis below, with supporting financial detail drawn from the 10-K and 10-Q.
Company Overview
Danaher Corporation is a diversified science and technology company operating across life sciences and diagnostics instrumentation, with a global commercial footprint spanning subsidiaries in both U.S. and non-U.S. markets served through direct sales, representatives, and distributors. The company is incorporated in Delaware, headquartered at 2200 Pennsylvania Avenue N.W., Washington, D.C., and lists its common stock and multiple series of senior notes on the New York Stock Exchange under the ticker DHR. Danaher operates across segments serving high-growth markets and has a long history of strategic acquisitions as a core part of its growth model.
AI-generated summary based on SEC filings. May contain errors. See disclosure
Investment Risk Score
BULLISHFull DHR Stock Risk Report
The integrated analysis — primary risk driver in plain language, expected shareholder outcome, what would materially change the view, and what moves the stock. One-time $7.99, lifetime access for DHR.
DHR Risk Summary
Danaher presents as a financially sound, large-cap life science and instrumentation platform with a shareholder-aligned capital structure: share count has declined through active buybacks, retained earnings stand at $46.9 billion as of December 31, 2025, long-term debt of $18.4 billion is conventional fixed-rate in structure, and the company declared and paid $878 million in dividends during…